Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab for treatment-refractory antibody-mediated diseases in neurology.
Scheibe F, Ostendorf L, Prüss H, Radbruch H, Aschman T, Hoffmann S, Blau IW, Meisel C, Alexander T, Meisel A. Scheibe F, et al. Eur J Neurol. 2022 Jun;29(6):1847-1854. doi: 10.1111/ene.15266. Epub 2022 Feb 10. Eur J Neurol. 2022. PMID: 35098616
METHODS: In this retrospective, single-center case series, seven patients with autoantibody-driven neurological autoimmune diseases (autoimmune encephalitis, n = 5; neurofascin antibody-associated chronic inflammatory demyelinating polyneuropathy associated with sporadic late ons …
METHODS: In this retrospective, single-center case series, seven patients with autoantibody-driven neurological autoimmune diseases (autoimm …
Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes.
Naddaf E, Milone M, Kansagra A, Buadi F, Kourelis T. Naddaf E, et al. Neurology. 2019 Jul 16;93(3):e298-e305. doi: 10.1212/WNL.0000000000007777. Epub 2019 Jun 5. Neurology. 2019. PMID: 31167932
OBJECTIVE: To describe the clinical phenotype, long-term treatment outcome, and overall survival of sporadic late-onset nemaline myopathy (SLONM) with or without a monoclonal protein (MP). ...A total of 7/9 (78%) patients receiving IV immunoglobulin (IVIg), 6/8 …
OBJECTIVE: To describe the clinical phenotype, long-term treatment outcome, and overall survival of sporadic late-onset nemaline m …
Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein.
Kotchetkov R, Susman D, Bhutani D, Broch K, Dispenzieri A, Buadi FK. Kotchetkov R, et al. Int J Cancer. 2021 Jun 1;148(11):2807-2814. doi: 10.1002/ijc.33483. Epub 2021 Feb 12. Int J Cancer. 2021. PMID: 33529362 Free article.
Sporadic late-onset nemaline myopathy (SLONM) associated with monoclonal protein (MP) is a rare disease with an aggressive, and often fatal course. ...Neurological improvement in the nonchemotherapy group (N = 25) was observed in 52% of patients: 8% reached m …
Sporadic late-onset nemaline myopathy (SLONM) associated with monoclonal protein (MP) is a rare disease with an aggressive, an …